Viscoelastic synthetic antigen-presenting cells for augmenting the potency of cancer therapies
The use of synthetic antigen-presenting cells to activate and expand engineered T cells for the treatment of cancers typically results in therapies that are suboptimal in effectiveness and durability. Here we describe a high-throughput microfluidic system for the fabrication of synthetic cells mimicking the viscoelastic and T-cell-activation properties of antigen-presenting cells. Compared with rigid or elastic microspheres, the synthetic viscoelastic T-cell-activating cells (SynVACs) led to substantial enhancements in the expansion of human CD8
Institutions
Authors
Funding
Intravascular Deployment of a Wirelessly Powered Micro-PacerIntegrating Volumetric Light-Field with Computational Fluid Dynamics to Study Myocardial Trabeculation and FunctionCalifornia Institute for Regenerative Medicine (CIRM) Grant DISC2-14169Shear stress and light-field to elucidate the initiation of cardiac outflow tractU.S. Department of Health & Human Services | National Institutes of Health (NIH) Grant NHLBI T32HL144449California Institute for Regenerative Medicine (CIRM) Grant DISE2-11157UCLA and Caltech integrated Cardiovascular Medicine for Bioengineers (iCMB)Regulation of cell reprogramming by matrix stiffnessStem Cell-Engineered Invariant Natural Killer T Cells for Cancer TherapyRegulation of cell reprogramming by matrix stiffnessElectrochemical Impedance Spectroscopy to Assess Metabolically Active PlaqueShear stress and light-field to elucidate the initiation of cardiac outflow tractStem Cell-Engineered Invariant Natural Killer T Cells for Cancer Therapy